abs89.txt	background		in	the	spartan	trial	addition	of	apalutamide	to	androgen	deprivationtherapy	as	compared	with	placebo	plus	deprivation	therapy	significantly	improved	metastasis-free	survival	men	non-metastaticcastration-resistant	prostate	cancer	who	were	at	high	risk	for	development	ofmetastases	we	aimed	investigate	effects	versus	placeboadded	on	health-related	quality	life	(hrqol)	methods	is	a	multicentre	international	randomised	phase	3	participants	aged	18	years	or	older	prostate-specific	antigen	doubling	timeof	10	months	less	and	concentration	2	ng/ml	ormore	serum	patients	randomly	assigned	(2	1)	240	mg	oral	apalutamideper	day	matched	androgendeprivation	using	an	interactive	voice	randomisation	system	permutedblock	was	used	according	three	baseline	stratificationfactors	time	(>6	vs	≤6	months)	use	ofbone-sparing	drugs	(yes	no)	presence	local-regional	nodal	disease	(n0vs	n1)	each	treatment	cycle	28	days	primary	endpoint	wasmetastasis-free	unblinded	july	2017	thisprespecified	exploratory	analysis	assessed	hrqol	functionalassessment	therapy-prostate	(fact-p)	eq-5d-3l	questionnaires	whichwe	collected	1	(before	dose)	treatmentcycles	1-6	every	two	cycles	from	7	13	everyfour	thereafter	this	study	registered	clinicaltrials	gov	numbernct01946204	findings	between	oct	14	2013	dec	15	2016	1207patients	receive	(n=806)	(n=401)	clinical	cutoffdate	may	19	median	follow-up	overallsurvival	20·3	(iqr	14·8-26·6)	fact-p	total	subscale	scores	wereassociated	preservation	29	theapalutamide	group	there	similar	results	meanfor	score	both	groups	consistentwith	general	population	norm	us	adult	meanpatient-reported	outcome	over	show	that	maintained	frombaseline	after	initiation	timeamong	receiving	least-squares	mean	changefrom	shows	deterioration	more	apparent	placebogroup	interpretation	asymptomatic	high-risk	ofapalutamide	considered	whoreceived	had	longer	tosymptomatic	progression	than	did	those	received	while	preservinghrqol	funding	janssen	research	&
